Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quentin M Anstee

Showing results (21-30 of 261) with videos related to

Pageof 27
Sort By:
Cell Metabolism|April 26, 2024
New and emerging treatments for metabolic dysfunction-associated steatohepatitisMonica A Tincopa, Quentin M Anstee, Rohit Loomba
BMJ (Clinical Research Ed.)|July 20, 2011
How big a problem is non-alcoholic fatty liver disease?Quentin M Anstee, Stuart McPherson, Christopher P Day
Current Opinion in Gastroenterology|March 17, 2015
Nonalcoholic fatty liver disease: new treatmentsTimothy Hardy, Quentin M Anstee, Christopher P Day
Clinics and Research in Hepatology and Gastroenterology|May 17, 2011
The role of hypercoagulability in liver fibrogenesisQuentin M Anstee, Ameet Dhar, Mark R Thursz
Journal of Hepatocellular Carcinoma|April 15, 2021
NAFLD-Associated HCC: Progress and OpportunitiesDaniel Geh, Quentin M Anstee, Helen L Reeves
Journal of Hepatology|September 21, 2020
Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease"Yasaman Vali, Quentin M Anstee, Patrick M Bossuyt
Gastroenterology|February 14, 2016
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver DiseaseQuentin M Anstee, Devanshi Seth, Christopher P Day
Nature Reviews. Gastroenterology & Hepatology|March 20, 2013
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosisQuentin M Anstee, Giovanni Targher, Christopher P Day
Hepatology (Baltimore, Md.)|February 12, 2020
ReplyLai Wei, Pik Eu Jason Chang, Quentin M Anstee
Biochimica Et Biophysica Acta|August 16, 2011
Genetic modifiers of non-alcoholic fatty liver disease progressionQuentin M Anstee, Ann K Daly, Christopher P Day
Pageof 27

Showing results (21-30 of 261) with videos related to

Sort By:
Pageof 27
Cell Metabolism|April 26, 2024
New and emerging treatments for metabolic dysfunction-associated steatohepatitisMonica A Tincopa, Quentin M Anstee, Rohit Loomba
BMJ (Clinical Research Ed.)|July 20, 2011
How big a problem is non-alcoholic fatty liver disease?Quentin M Anstee, Stuart McPherson, Christopher P Day
Current Opinion in Gastroenterology|March 17, 2015
Nonalcoholic fatty liver disease: new treatmentsTimothy Hardy, Quentin M Anstee, Christopher P Day
Clinics and Research in Hepatology and Gastroenterology|May 17, 2011
The role of hypercoagulability in liver fibrogenesisQuentin M Anstee, Ameet Dhar, Mark R Thursz
Journal of Hepatocellular Carcinoma|April 15, 2021
NAFLD-Associated HCC: Progress and OpportunitiesDaniel Geh, Quentin M Anstee, Helen L Reeves
Journal of Hepatology|September 21, 2020
Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease"Yasaman Vali, Quentin M Anstee, Patrick M Bossuyt
Gastroenterology|February 14, 2016
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver DiseaseQuentin M Anstee, Devanshi Seth, Christopher P Day
Nature Reviews. Gastroenterology & Hepatology|March 20, 2013
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosisQuentin M Anstee, Giovanni Targher, Christopher P Day
Hepatology (Baltimore, Md.)|February 12, 2020
ReplyLai Wei, Pik Eu Jason Chang, Quentin M Anstee
Biochimica Et Biophysica Acta|August 16, 2011
Genetic modifiers of non-alcoholic fatty liver disease progressionQuentin M Anstee, Ann K Daly, Christopher P Day
Pageof 27